MedKoo Cat#: 464752 | Name: PD159206
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

PD-159206 is a nucleocapsid inhibitor. It exhibits good antiviral activity against HIV.

Chemical Structure

PD159206
PD159206
CAS#171744-42-6

Theoretical Analysis

MedKoo Cat#: 464752

Name: PD159206

CAS#: 171744-42-6

Chemical Formula: C26H32N2O6S2

Exact Mass: 532.1700

Molecular Weight: 532.67

Elemental Analysis: C, 58.63; H, 6.06; N, 5.26; O, 18.02; S, 12.04

Price and Availability

Size Price Availability Quantity
5mg USD 90.00 Ready to ship
10mg USD 150.00 Ready to ship
25mg USD 250.00 Ready to ship
50mg USD 450.00 Ready to ship
100mg USD 750.00 Ready to ship
200mg USD 1,350.00 Ready to ship
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
PD-159206; PD159206; PD 159206; CI 1013; CI-1013; CI1013; DIBA 4;
IUPAC/Chemical Name
N,N'-[Dithiobis(2,1-phenylenecarbonyl)]bis[isoleucine]
InChi Key
SUQDXZBTWJQATJ-QDGJQWLKSA-N
InChi Code
InChI=1S/C26H32N2O6S2/c1-5-15(3)21(25(31)32)27-23(29)17-11-7-9-13-19(17)35-36-20-14-10-8-12-18(20)24(30)28-22(26(33)34)16(4)6-2/h7-16,21-22H,5-6H2,1-4H3,(H,27,29)(H,28,30)(H,31,32)(H,33,34)/t15-,16-,21-,22-/m0/s1
SMILES Code
O=C(N[C@@H]([C@@H](C)CC)C(O)=O)C1=CC=CC=C1SSC2=CC=CC=C2C(N[C@@H]([C@@H](C)CC)C(O)=O)=O
Appearance
Solid powder
Purity
>95% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Biological target:
PD-159206 is a nucleocapsid inhibitor.
In vitro activity:
TBD
In vivo activity:
TBD

Preparing Stock Solutions

The following data is based on the product molecular weight 532.67 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Domagala JM, Gogliotti R, Sanchez JP, Stier MA, Musa K, Song Y, Loo J, Reily M, Tummino P, Harvey P, Hupe D, Sharmeen L, Mack D, Scholten J, Saunders J, McQuade T. 2,2'-Dithiobisbenzamides and 2-benzisothiazolones, two new classes of antiretroviral agents: SAR and mechanistic considerations. Drug Des Discov. 1997 May;15(1):49-61. PMID: 9332831.
In vitro protocol:
1. Domagala JM, Gogliotti R, Sanchez JP, Stier MA, Musa K, Song Y, Loo J, Reily M, Tummino P, Harvey P, Hupe D, Sharmeen L, Mack D, Scholten J, Saunders J, McQuade T. 2,2'-Dithiobisbenzamides and 2-benzisothiazolones, two new classes of antiretroviral agents: SAR and mechanistic considerations. Drug Des Discov. 1997 May;15(1):49-61. PMID: 9332831.
In vivo protocol:
1. Domagala JM, Gogliotti R, Sanchez JP, Stier MA, Musa K, Song Y, Loo J, Reily M, Tummino P, Harvey P, Hupe D, Sharmeen L, Mack D, Scholten J, Saunders J, McQuade T. 2,2'-Dithiobisbenzamides and 2-benzisothiazolones, two new classes of antiretroviral agents: SAR and mechanistic considerations. Drug Des Discov. 1997 May;15(1):49-61. PMID: 9332831.
1: Zhao X, Xu H, Li Y, Ma R, Qi Y, Zhang M, Guo C, Sun Z, Li Y. Proteomic profiling reveals dysregulated mitochondrial complex subunits responsible for myocardial toxicity induced by SiNPs. Sci Total Environ. 2023 Jan 20;857(Pt 1):159206. doi: 10.1016/j.scitotenv.2022.159206. Epub 2022 Oct 2. PMID: 36198348. 2: Poddalgoda D, Macey K, Hancock S. Derivation of biomonitoring equivalents (BE values) for zinc. Regul Toxicol Pharmacol. 2019 Aug;106:178-186. doi: 10.1016/j.yrtph.2019.04.018. Epub 2019 May 4. PMID: 31063796. 3: Ochiai A, Naya Y, Soh J, Ishida Y, Mizutani Y, Kawauchi A, Fujiwara T, Miki T. Efficacy of sildenafil as the first-step therapeutic tool for Japanese patients with erectile dysfunction. Int J Impot Res. 2005 Jul-Aug;17(4):339-42. doi: 10.1038/sj.ijir.3901318. PMID: 15829991. 4: Sharmeen L, McQuade T, Heldsinger A, Gogliotti R, Domagala J, Gracheck S. Inhibition of the early phase of HIV replication by an isothiazolone, PD 161374. Antiviral Res. 2001 Feb;49(2):101-14. doi: 10.1016/s0166-3542(00)00143-1. PMID: 11248362. 5: Domagala JM, Gogliotti R, Sanchez JP, Stier MA, Musa K, Song Y, Loo J, Reily M, Tummino P, Harvey P, Hupe D, Sharmeen L, Mack D, Scholten J, Saunders J, McQuade T. 2,2'-Dithiobisbenzamides and 2-benzisothiazolones, two new classes of antiretroviral agents: SAR and mechanistic considerations. Drug Des Discov. 1997 May;15(1):49-61. PMID: 9332831.